Lab Platform Provista operates a CLIA/CAP certified lab in Alpharetta, enabling rapid test development and deployment. This lab platform can support outsourced testing, co development, or regional service expansion through partnerships with clinics and hospitals.

Videssa Growth Videssa breast cancer blood test is a flagship product with potential for licensing, co commercialization, or expansion of women's health biomarkers. Opportunities include bundling with imaging services, entering adjacent markets, and pursuing payer-ready adoption programs.

Multi-disease Expansion Recent PCR testing launches across urinary tract infections, wounds, respiratory pathogens, and COVID show a willingness to diversify service lines. This creates sales opportunities for lab automation, sample processing, and multi-disease testing solutions.

Partnerships & Distribution As a small, growth-oriented company, Provista could accelerate market reach through strategic partnerships with larger diagnostic firms or distributors, enabling broader access to Videssa and other tests, and helping with payer negotiations.

Compliance & Reimbursement With CLIA/CAP operations and commercial tests, there is demand for data analytics, regulatory compliance support, and reimbursement strategy to speed adoption. Solutions such as data dashboards, coding guidance, and payer engagement services could drive sales.